RFIL +51% on Q1 result.
RKDA +44% on achieving key resistant starch wheat technology milestones, prepares for commercial launch.
TYME +22% as FDA has accepted its investigational new drug application allowing to initiate the planned Phase II clinical trial for SM-88 in pancreatic cancer.
KOOL +9% as Cesca inks deal in Asia for CAR-T cell processing services.
OTIV +6% on new purchase order to deliver 8,000 of OTI"s Uno-advanced 8 secure contactless NFC readers to the Smart ATM market.
EXPR +5% on Q4 result.
ALOT +5% on Q4 result.Nguồn: seekingalpha.com